#South Korea #Seoul #Rznomics #RZ-001 #HCC

Rznomics Presents Encouraging Results for RZ-001 in Hepatocellular Carcinoma

On April 19, 2026, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California, Rznomics showcased interim clinical findings from its study of RZ-001, an innovative RNA editing-based treatment aimed at hepatocellular carcinoma (HCC). The presentation, conducted by Professor Yoon-Jun Kim from Seoul National University Hospital, evoked significant interest in the oncology community for its remarkable efficacy and safety profiles.

Study Overview and Results

The ongoing study investigates RZ-001's performance in patients suffering from HCC who have shown resistance to or are ineligible for transarterial chemoembolization (TACE). Notably, these participants had not undergone any prior systemic therapy, highlighting the investigational aspect of RZ-001 in an area with considerable unmet medical needs.

The efficacy data presented revealed positive outcomes, with an objective response rate (ORR) of 38.5% based on RECIST v1.1 criteria and an impressive unconfirmed ORR of 46.2%. However, it was the modified RECIST (mRECIST) results that truly distinguished RZ-001, achieving an ORR of 61.5%, including a complete response (CR) rate of 23%. These results strongly suggest that RZ-001 may induce profound tumor responses, emphasizing the potential of this candidate in the battle against HCC.

Interim analysis details indicate a distinction between confirmed and unconfirmed responses. Confirmed responses undergo subsequent assessments to validate their accuracy, while unconfirmed responses reflect preliminary observations where patients have shown at least a 30% reduction in tumor size at first evaluation.

Safety Profile

Rznomics also highlighted the safety aspect of RZ-001, reporting no Grade 3 or higher adverse events attributed to the treatment itself. Five instances of such adverse events were noted with the combination therapy agents, which included conditions like hypertension and gastrointestinal bleeding. The absence of severe side effects related to RZ-001 provides reassurance regarding its safety, a critical consideration for both clinicians and patients.

CEO's Remarks and Future Prospects

Seong-Wook Lee, the CEO of Rznomics, remarked, "Presenting our findings at AACR marks a significant milestone in our validation journey for RZ-001. The early efficacy and tolerable safety signals we have observed reinforce our belief in RZ-001's potential as a groundbreaking therapeutic for HCC." He further noted that the findings might bolster the practical application of Rznomics' RNA trans-splicing ribozyme platform technology across various treatment scenarios.

The Significance of Hepatocellular Carcinoma

Hepatocellular carcinoma is the leading form of primary liver cancer, with a dire need for innovative treatment strategies addressing the complexities of the disease. Often diagnosed at advanced stages, HCC poses a serious health challenge, making therapies that promise deeper and sustained responses crucial. RZ-001's introduction may offer hope to patients who previously had limited options due to refractoriness to TACE or ineligibility for advanced systemic treatments.

We look forward to further developments from Rznomics as they continue to explore this promising avenue in liver cancer therapeutics. Rznomics is not only poised to reshape treatment modalities for HCC but also herald a new era in RNA-based therapies, reflecting significant advancements in clinical research and patient care strategies.

For more details about Rznomics and its clinical advancements, please visit www.rznomics.com.